With a fresh phase 3 win for Kerendia, Bayer is one step closer to pushing the ascendant drug into a much broader population ...

If Kerendia secures a label expansion, it would become available to more than half of the overall CKD patient population who have a non-diabetic form of the disease.

Kerendia has hit the spot in another phase 3 trial that could extend its use as a treatment for patients with chronic kidney disease (CKD). Extending the label for Kerendia is a strategic priority for ...